lumateperone - Page 1 | CARLAT PUBLISHING

Lumateperone in Bipolar Depression

January 31, 2022

John C. Raiss, MD. Dr. Raiss has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In December 2021, the FDA approved lumateperone (Caplyta) for bipolar I and II depression, and here we report on one of the trials that led to that approval.

RESEARCH UPDATE

A Novel Treatment for Methamphetamine Use Disorder

January 31, 2022

David A. Moltz, MD.

David A. Moltz, MD. Dr. Moltz has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

With so few pharmacologic options for methamphetamine use disorder, a large trial from The New England Journal of Medicine suggest bupropion and naltrexone are worth exploring.

A New Antipsychotic for Bipolar Depression

July 30, 2020

Chris Aiken, MD.

Chris Aiken, MD. Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

An atypical antipsychotic with a novel mechanism shows promise in bipolar depression.

Lumateperone and lemborexant

March 9, 2020

The antipsychotic lumateperone (Caplyta) and the hypnotic lemborexant (Dayvigo) are the newest in their class. Both of them claim to improve on the safety of older medications, and we look at the data to see how those claims hold up.